Biohaven meanwhile recorded Nurtec ODT sales of $462 million in 2021, a performance that prompted Pfizer to stump up $500 million upfront for rights to the drug outside the US last November.

Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...

| Project Optimus is changing the landscape of oncology drug development by redefining dose optimization standards. Learn how ...

The traditional film model for particle dissolution assumes that flux behavior depends primarily on particle size relative to ...

Getty Images Lepodisiran — an experimental drug made by the pharmaceutical company Eli Lilly — has been found to slash this type of cholesterol by nearly 94% after a single dose. Participants ...

As with its predecessor, the new drug candidate, Jun13296, targets a different viral protein than Paxlovid does and works ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be untreatable, for up to one year. Lipoprotein(a) is a type of cholesterol ...

The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

such as cancer therapies Adcetris and Padcev along with migraine drug Nurtec ODT, that should help offset the revenue declines. In addition, Pfizer's pipeline looks promising with 115 programs in ...

largely on the promise of Nurtec ODT, which made almost $1.4 billion in sales in 2023 and has been predicted to have reached more than $1.8 billion last year. The drug is approved both to treat ...

Researchers say they have discovered a new class of antibiotics that could treat drug-resistant bacteria, the first to reach the market in nearly three decades. The new molecule, called ...